Entities / Company
Merck.
public company in Indonesia
- Reports this week
- 1
- Active events
- 0
- Connections
- 264
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
Merck forged a strategic alliance with R-Pharm on November 1, 2026.Some support1 report
-
AstraZeneca formed a partnership with Daiichi Sankyo regarding Enhertu, and also established a profit-sharing deal with Merck for Lynparza.Some support4 reports1 development inside
-
The Schwab U.S. Dividend Equity ETF now includes Procter & Gamble, Abbott Laboratories, and Merck among its top 10 holdings.Some support2 reports
-
Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.Well supported51 reports2 developments inside
-
Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.Well supported9 reports7 developments inside
-
Moderna and Merck developed a new therapy.Some support8 reports1 development inside
-
Moderna and Merck developed the intismeran autogene therapy.Some support1 report
-
FDA approved Rasonque for pancreatic cancer, while Revolution Medicines evaluates therapy with Merck's Keytruda and compares its market cap to Eli Lilly.Some support1 report
-
Merck launched its GBA Innovation Center in Shenzhen and signed an agreement to establish a center in Hong Kong.Some support1 report
-
Moderna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.Well supported3 reports
-
AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.Speculative1 report1 development inside
-
Eli Lilly and Merck are combining therapies in clinical trials.Some support1 report
-
Merck and Moderna funded an Australian-led clinical trial involving the University of Sydney.Some support1 report1 development inside
-
Moderna's therapy combined with Merck's drug in an Australian-led clinical trial.Some support1 report
-
CEPI provided support for the Tumaini trial, where a Merck vaccine is being administered in the Democratic Republic of the Congo.Some support1 report
-
Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.Some support4 reports
-
Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.Well supported9 reports
-
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Well supported21 reports10 developments inside
-
Moderna and Merck released study results, while execution staff warned of potential issues during Christa Pike's execution attempt.Some support1 report
-
Merck participates in a cancer vaccine study, with a researcher based at MD Anderson Cancer Center in Houston.Some support2 reports
-
Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.Well supported14 reports2 developments inside
-
Friedrich Merz is scheduled for an opening keynote in Seoul while Merck plans a €300M investment in Daejeon.Some support1 report
-
The Schwab U.S. Dividend Equity ETF holds Abbott Laboratories, Merck, and Coca-Cola as among its top holdings.Well supported7 reports
-
Moderna and Merck reported a landmark result from their melanoma study, while SanDisk and Dell were discussed in stock market analysis.Well supported4 reports1 development inside
-
Merck is expanding its operations in Montgomery County.Some support1 report
-
Amgen and Merck are currently competing against each other in the market for investor capital.Some support4 reports
-
Merck is expanding its R&D and manufacturing operations across Kansas, Delaware, Virginia, and Pennsylvania.Some support1 report
-
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Well supported5 reports2 developments inside
-
Uğur Şahin and Özlem Türeci plan to leave BioNTech, while Moderna and Merck advance their combined vaccine study.Some support1 report
-
A new facility has opened in Sheboygan Falls, strengthening the area's global profile through investment.Some support1 report1 development inside
-
Merck developed the experimental eye treatment remigromig, leading Jefferies to cut sales forecasts due to trial concerns.Some support1 report
-
A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.Some support1 report2 developments inside
One to three months ago
-
Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.Well supported3 reports3 developments inside
-
Seagate Technology, Merck, and Hewlett Packard Enterprise paid quarterly dividends on October 8, 2026.Some support1 report
-
Moderna and Merck conducted a study on mRNA vaccine while Rob Sand campaigned for Iowa governor, proposing plans to tackle cancer.Some support1 report
-
Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Well supported4 reports
-
Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.Some support1 report
-
Janus Henderson is backing biotech reverse mergers while dueling drug data emerges between involved companies.Some support2 reports
-
Bank of America led Merck's $5 billion financing deal, alongside bond sales by automakers, amid market anticipation of FED rate decisions.Some support1 report1 development inside
-
Bank of America shared insights from Merck's CMO regarding the ongoing financing deal.Some support1 report
-
Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.Some support1 report
-
Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.Some support2 reports
-
Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.Some support6 reports
-
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.Speculative1 report2 developments inside
-
Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.Some support2 reports
-
Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.Well supported4 reports
-
ISS research contributed to the formulation of Keytruda, a medical application involving Chief Engineer Ariel Ekblaw and Michael Roberts.Some support1 report
-
Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.Some support1 report1 development inside
-
Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.Some support3 reports4 developments inside
-
Merck's Animal Health segment is performing well, and the company discussed transformation during a meeting with Morgan Stanley.Some support1 report
-
A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.Well supported3 reports
-
Eli Lilly, Merck, and Novo Nordisk are competing in the GLP-1 economics market, with Novo Nordisk referencing a SUSE cardiovascular trial.Some support3 reports
-
OPKO Health announced asset sales, advanced an EBV vaccine Phase 1 trial, and saw FDA approval for prostate cancer screening.Well supported5 reports
-
Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.Some support3 reports1 development inside
-
Dr. Cannon gained experience at Merck, involving Lindus Therapeutics.Some support1 report
-
Moderna, Tempus, and Merck partnered on the INTerpath-001 trial, which focuses on indications that are covered by Medicare.Some support2 reports
-
Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.Some support1 report
-
Robert F. Kennedy Jr. collaborated on major cancer vaccine trials while criticizing mRNA technology and its potential funding.Some support2 reports
-
Merck's stock price increased following positive drug performance involving Summit Therapeutics.Some support1 report
-
Companies including UnitedHealth Group, Procter & Gamble, Abbott Laboratories, and Merck are noted as being included in high-quality dividend ETFs.Some support1 report1 development inside
No events began in the chosen period. Widen it, or reset.
What's reaching Merck
Events traced to Merck, step by step, newest first- New chronic cough drug may increase competition for MerckNew chronic cough drug may increase competition for MerckPossible
- India's growing vaccine ecosystem could challenge Merck's market positionIncreased vaccine production capacity in India may intensify global competition for Merck.Possible
- Merck may benefit from defensive capital rotation into healthcareMerck could benefit from defensive capital rotation into healthcare stocksPossible
- Roche's new oncology collaboration may intensify competition for MerckRoche's new oncology collaboration may intensify competition for MerckPossible
- How will the generic ANDA submission for Sitagliptin affect Merck?Generic competitor challenges market exclusivity of Sitagliptin tabletsReported
Around Merck this week
News at the entities that move Merck most-
Moderna StructuralArbutus Biopharma filed patent enforcement lawsuits against Pfizer and sued Moderna regarding LNP patent infringement.Moves Merck
-
FDA StructuralDBV Technologies is seeking regulatory acceptance for its product from the FDA.Moves Merck
-
Eli Lilly and Company OperationalEli Lilly and Company is utilizing major wholesale distribution partners, including Cardinal Health and McKesson Corp, in its operational structure.Moves Merck
-
Bank of America OperationalBank of America, Deutsche Bank, and Truist Financial reduced their price targets for Costco on November 11, 2026.Moves Merck
-
Health Canada StructuralHealth Canada authorized technology developed in Australia, prompting Hamilton burn centre specialists to be sent to Alberta.Moves Merck
-
Davis StructuralMagistrate Brown is hearing the case of Davis, who is defended by James Oxley, while Davis resides in Indonesia.Moves Merck
Connections
The 40 strongest of 264, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Silence Therapeutics Structural
Merck acquired Silence Therapeutics, establishing a parent-subsidiary relationship.
-
Moderna Structural
Moderna and Merck maintain a deep structural partnership, jointly developing and supplying personalized mRNA cancer vaccines and combination therapies.
-
FDA Structural
FDA mandates regulatory oversight and grants market approval for Merck's pharmaceutical products.
-
Verona Pharma Structural
Merck acquired Verona Pharma for $10 billion, integrating its pipeline and products into Merck's operations.
-
Dean Y. Li Structural
Dean Y. Li serves as president of Merck Research Laboratories.
-
Verona Structural
Merck acquired Verona, establishing an ownership relationship that integrates Verona's assets into Merck's drug portfolio.
-
MSD Structural
MSD functions as the regional name and subsidiary of Merck outside of the US and Canada.
-
Davis Structural
Davis serves as the Chairman and CEO of Merck.
Show all 40 connections
-
Azad Bonni Structural
Azad Bonni holds the role of senior vice president at Merck.
-
Tempus Structural
Tempus supplies diagnostic data and AI tools and partners with Merck on clinical trials.
-
OGN Structural
OGN is a subsidiary of Merck, having been spun off from the parent company in 2021.
-
Merck Animal Health Structural
Merck Animal Health operates as a formal division of the larger corporate entity, Merck & Co., Inc.
-
Eli Lilly and Company Operational
Eli Lilly and Merck are direct, high-stakes competitors in the pharmaceutical market, particularly in GLP-1 and oncology therapeutics, frequently comparing sales and market positioning.
-
Bank of America Operational
Bank of America actively engages with Merck through financial services, market analysis, and information sharing.
-
Zoetis Operational
Zoetis and Merck actively compete in the healthcare market, particularly in animal and equine health segments.
-
Pfizer Operational
Pfizer and Merck actively compete in various drug markets, including oncology, and their financial performance is mutually compared by the market.
-
Rob Davis Structural
Rob Davis serves as the Chairman and CEO of Merck.
-
Johnson & Johnson Operational
Johnson & Johnson and Merck are major pharmaceutical companies actively competing for market share in specialized drug sectors like oncology and PAH.
-
Cidara Therapeutics Structural
Merck acquired Cidara Therapeutics, establishing a current parent-subsidiary relationship.
-
Control Data Corporation Operational
CDC evaluates and recommends Merck's pharmaceutical products, facing current allegations of data falsification.
-
Medicare Transactional
Merck engages in specific pricing and access negotiations with Medicare regarding its drugs and services.
-
Health Canada Structural
Health Canada regulates and approves Merck's pharmaceutical products, enabling their market access in Canada.
-
Amgen Operational
Amgen and Merck are active competitors in the biosimilar market and compete for investor capital and market growth.
-
Animal Health Structural
Animal Health functions as a specific, integrated business segment within the larger Merck corporate structure.
-
Gilead Sciences Structural
Gilead relies on Merck's products for combination therapies and the companies are actively partnering on new drug development.
-
AstraZeneca Operational
AstraZeneca and Merck actively compete in the oncology space while maintaining a strategic partnership involving co-marketing and profit-sharing deals.
-
Narendra Modi Structural
The relationship is defined by the government-led procurement and utilization of Merck's products for the national vaccination campaign.
-
Novartis Operational
The companies are direct competitors in the advanced therapies market and are frequently grouped as top holdings in sector-specific ETFs.
-
Vassiliki Karantza Structural
Vassiliki Karantza is employed as an Associate Vice President at Merck.
-
DRC Transactional
Merck provided the Ervebo vaccine for use in a clinical trial conducted in the DRC.
-
CoreWeave Structural
CoreWeave plans to establish its facility on land previously owned by Merck.
-
Rob Davis Structural
Rob Davis serves as the chairman and CEO of Merck.
-
Robert F. Kennedy Jr. Operational
A promotes B's products through recommendations but also targets B through product liability lawsuits.
-
Daiichi Operational
Merck and Daiichi are engaged in a formal co-development partnership for a Phase III clinical study following the acquisition of co-development rights.
-
OPKO Health (Ireland) Operational
OPKO Health and Merck are actively collaborating on the development and advancement of an Epstein-Barr virus vaccine candidate.
-
Hyperion Structural
Hyperion's clinical trial data is utilized by Merck in its drug development and evaluation processes.
-
GSK Operational
GSK and Merck are direct competitors in the market due to their production and sale of combination MMR shots.
-
Hoffmann-La Roche Operational
Roche and Merck are direct competitors in the immuno-oncology and PD-L1 inhibitor markets.
-
Ligand Pharmaceuticals Structural
The companies are in a partnership where Merck funds Ligand's drug development and provides royalty revenue from its portfolio.
-
Veeva Systems Operational
Veeva Systems provides software and strategic services to Merck, which commits to implementing these solutions.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
19 events- Moderna and Merck developed the intismeran autogene therapy.
- FDA approved Rasonque for pancreatic cancer, while Revolution Medicines evaluates therapy with Merck's Keytruda and compares its market cap to Eli Lilly.
- Merck launched its GBA Innovation Center in Shenzhen and signed an agreement to establish a center in Hong Kong.
- Eli Lilly and Merck are combining therapies in clinical trials.
- Merck and Moderna funded an Australian-led clinical trial involving the University of Sydney.
- Moderna's therapy combined with Merck's drug in an Australian-led clinical trial.
- CEPI provided support for the Tumaini trial, where a Merck vaccine is being administered in the Democratic Republic of the Congo.
- Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.
- Moderna and Merck released study results, while execution staff warned of potential issues during Christa Pike's execution attempt.
- Merck participates in a cancer vaccine study, with a researcher based at MD Anderson Cancer Center in Houston.
- Friedrich Merz is scheduled for an opening keynote in Seoul while Merck plans a €300M investment in Daejeon.
- Moderna and Merck reported a landmark result from their melanoma study, while SanDisk and Dell were discussed in stock market analysis.
- Merck is expanding its operations in Montgomery County.
- Merck is expanding its R&D and manufacturing operations across Kansas, Delaware, Virginia, and Pennsylvania.
- Uğur Şahin and Özlem Türeci plan to leave BioNTech, while Moderna and Merck advance their combined vaccine study.
- A new facility has opened in Sheboygan Falls, strengthening the area's global profile through investment.
- Merck developed the experimental eye treatment remigromig, leading Jefferies to cut sales forecasts due to trial concerns.
- Seagate Technology, Merck, and Hewlett Packard Enterprise paid quarterly dividends on October 8, 2026.
- Moderna and Merck conducted a study on mRNA vaccine while Rob Sand campaigned for Iowa governor, proposing plans to tackle cancer.
September 2026
15 events- The Schwab U.S. Dividend Equity ETF now includes Procter & Gamble, Abbott Laboratories, and Merck among its top 10 holdings.
- Amgen and Merck are currently competing against each other in the market for investor capital.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.
- Janus Henderson is backing biotech reverse mergers while dueling drug data emerges between involved companies.
- Bank of America shared insights from Merck's CMO regarding the ongoing financing deal.
- Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.
- Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
- Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.
- Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.
- ISS research contributed to the formulation of Keytruda, a medical application involving Chief Engineer Ariel Ekblaw and Michael Roberts.
- Merck's Animal Health segment is performing well, and the company discussed transformation during a meeting with Morgan Stanley.
- Dr. Cannon gained experience at Merck, involving Lindus Therapeutics.
- Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.
- Merck's stock price increased following positive drug performance involving Summit Therapeutics.
Show 3 earlier months
August 2026
10 events- Moderna and Merck developed a new therapy.
- Moderna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
- Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.
- A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.
- Eli Lilly, Merck, and Novo Nordisk are competing in the GLP-1 economics market, with Novo Nordisk referencing a SUSE cardiovascular trial.
- Moderna, Tempus, and Merck partnered on the INTerpath-001 trial, which focuses on indications that are covered by Medicare.
- Robert F. Kennedy Jr. collaborated on major cancer vaccine trials while criticizing mRNA technology and its potential funding.
July 2026
2 eventsJune 2026
13 events- AstraZeneca formed a partnership with Daiichi Sankyo regarding Enhertu, and also established a profit-sharing deal with Merck for Lynparza.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.
- Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
- Bank of America led Merck's $5 billion financing deal, alongside bond sales by automakers, amid market anticipation of FED rate decisions.
- Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
- OPKO Health announced asset sales, advanced an EBV vaccine Phase 1 trial, and saw FDA approval for prostate cancer screening.
- Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.
- Companies including UnitedHealth Group, Procter & Gamble, Abbott Laboratories, and Merck are noted as being included in high-quality dividend ETFs.